Adverse Pregnancy Outcomes Associated With in Utero Exposure to Multiple Sclerosis Disease-Modifying Therapies in France: A Nationwide Cohort Study

被引：0
|
作者：
Swital, Morgane [1 ]
Drouin, Jerome [1 ]
Miranda, Sara [2 ]
Botton, Jeremie [1 ]
Dray-Spira, Rosemary [1 ]
机构：
[1] EPI PHARE, French Natl Agcy Med & Hlth Prod Safety ANS, French Natl Hlth Insurance CNAM, 143-147 Blvd Anatole France, F-93285 St Denis, France
[2] EPI PHARE, ANSM, CNAM, Paris, France
来源：
PHARMACOEPIDEMIOLOGY AND DRUG SAFETY | 2024年 / 33卷
关键词：
D O I：
暂无
中图分类号：
R1 [预防医学、卫生学];
学科分类号：
1004 ; 120402 ;
摘要：
190
引用
收藏
页码：61 / 62
页数：2
相关论文
共 50 条
  • [31] Adverse psychiatric effects of disease-modifying therapies in multiple Sclerosis: A systematic review
    Gasim, Majid
    Bernstein, Charles N.
    Graff, Lesley A.
    Patten, Scott B.
    El-Gabalawy, Renee
    Sareen, Jitender
    Bolton, James M.
    Marriott, James J.
    Fisk, John D.
    Marrie, R. A.
    MULTIPLE SCLEROSIS AND RELATED DISORDERS, 2018, 26 : 124 - 156
  • [32] Work Productivity Outcomes Associated with Ocrelizumab Compared with Other Disease-Modifying Therapies for Multiple Sclerosis
    Edward E. Neuberger
    Ibrahim M. Abbass
    Eddie Jones
    Natalie J. Engmann
    Neurology and Therapy, 2021, 10 : 183 - 196
  • [33] Factors Associated with Patient Preferences for Disease-Modifying Therapies in Multiple Sclerosis
    Hincapie, Ana L.
    Penm, Jonathan
    Burns, Craig F.
    JOURNAL OF MANAGED CARE & SPECIALTY PHARMACY, 2017, 23 (08): : 822 - 830
  • [34] Work Productivity Outcomes Associated with Ocrelizumab Compared with Other Disease-Modifying Therapies for Multiple Sclerosis
    Neuberger, Edward E.
    Abbass, Ibrahim M.
    Jones, Eddie
    Engmann, Natalie J.
    NEUROLOGY AND THERAPY, 2021, 10 (01) : 183 - 196
  • [35] Pregnancy and disease-modifying therapies in patients with relapsing-remitting multiple sclerosis
    Oztekin, N. S.
    Oztekin, M. F.
    MULTIPLE SCLEROSIS, 2006, 12 : S95 - S96
  • [36] Disease-modifying therapy of paediatric onset multiple sclerosis. A nationwide Danish cohort study
    Erdal, J. L.
    Kopp, T. Iskov
    Blinkenberg, M.
    Petersen, T.
    Ravnborg, M.
    Chalmer, T.
    Sorensen, P. Soelberg
    Magyari, M.
    MULTIPLE SCLEROSIS JOURNAL, 2018, 24 : 905 - 906
  • [37] Initial high-efficacy disease-modifying therapy in multiple sclerosis A nationwide cohort study
    Buron, Mathias Due
    Chalmer, Thor Ameri
    Sellebjerg, Finn
    Barzinji, Ismael
    Christensen, Jeppe Romme
    Christensen, Mette Kirstine
    Hansen, Victoria
    Illes, Zsolt
    Jensen, Henrik Boye
    Kant, Matthias
    Papp, Viktoria
    Petersen, Thor
    Rasmussen, Peter Vestergaard
    Schafer, Jakob
    Theodorsdottir, Asta
    Weglewski, Arkadiusz
    Sorensen, Per Soelberg
    Magyari, Melinda
    NEUROLOGY, 2020, 95 (08) : E1041 - E1051
  • [38] Multiple sclerosis disease-modifying therapy and pregnancy
    Miller, Aaron E.
    MULTIPLE SCLEROSIS JOURNAL, 2016, 22 (06) : 715 - 716
  • [39] Infections in patients with multiple sclerosis treating with disease-modifying therapies: a risk assessment cohort study
    Fattahi, M. R.
    Sahraian, M. A.
    Mesgarof, M. A.
    Valizadeh, A.
    Azimi, A.
    Moghadasi, A. N.
    Doosti, R.
    Hemmati, Z.
    Abouzari, F.
    Ghashti, S. Hamtaei
    MULTIPLE SCLEROSIS JOURNAL, 2022, 28 (3_SUPPL) : 866 - 867
  • [40] The Impact of Adherence to Disease-Modifying Therapies on Functional Outcomes in Veterans with Multiple Sclerosis
    Rabadi, Meheroz H.
    Just, Kimberly
    Xu, Chao
    JOURNAL OF CENTRAL NERVOUS SYSTEM DISEASE, 2021, 13
12345